VC  The Column Group

https://www.thecolumngroup.com





     Office Locations:

1 Letterman Drive
Building D, Suite DM-900
San Francisco, CA 94129
Phone: 415-865-2050
Fax: 415-255-2048

 

Stages:

  • Early
  • Expansion
  • Growth
  • Seed


 

Industries:

  • Life Sciences & Healthcare

  •  

    Description:

    The Column Group is a venture capital firm dedicated to creating the next generation of biotechnology companies. The firm will invest in approximately 10-12 disease-focused drug discovery companies (per fund), each with the potential to become a leader in their respective field(s). Typically, Column will commit $15M to $30M per company, fostering their growth from seed and early stage to later stages of development. The Column Group will primarily focus on early stage drug discovery companies, an area currently underserved by many biotech venture capital funds. The firm is currently evaluating opportunities in the areas of cancer, inflammation, infectious disease, metabolic disorders, cardiovascular disease and nervous system disorders. TCG has $2.2 billion in assets under management.


     

    Funds:


      Fund Name


      Amount


      Date

    Get funds under management for this firm including Fund name, Dollar size of fund raise, and Vintage with a National Database subscription or Silicon Valley Database subscription.



    Investment Firm Key

       VC = Venture Capital
       PE = Private Equity
       A = Angel
       I = Incubator
       MB = Merchant Bank
       VD = Venture Debt
       FI = Family Investment Office
       FOF = Fund of Funds
       ED = Economic Development Office   
       TT = Technology Transfer Office
       CVC = Corporate Venture Capital
       SEC = Secondary Purchaser
       HF = Hedge Fund/Mutual Fund
       
       
       
    COMPANY STAGEREVENUE
    Venture Capital
    Seed Stage
    (includes "pre-seed," or
    concept stage)
    No Revenue
    Early StageMinimal
    Revenue
    Growth Stage
    (also called Mid-stage)
    $2M-$7M
    Expansion Stage
    (also called Late-stage)
    $7M and greater
    Private Equity
    Lower Middle Market$10M-$249M
    Middle Market$250M-$499M
    Upper Middle Market$500M-$1B
    Large Cap>$1B
       
       
     

    Investment Team:


    Name   Title
    Get the complete investment team + individual email addresses for investment team partners. Get personal images, LinkedIn links, investment specialties, office locations and more with a National Database subscription or Silicon Valley Database subscription.
    David V. Goeddel Ph.D. Managing Partner
    J.J Kang Ph.D Venture Partner
    Larry Lasky Ph.D Partner
    Peter Svennilson Managing Partner and Founder
    Robert Tjian Discovery Partner

     

    Recent Funding Events (trailing 12 months):


      Date


      Name


      State


      Amount


      Stage


      01/06/2023


      Synthekine


      CA


      $100,000,000


      Series C


      11/15/2022


      Casma Therapeutics


      MA


      $46,000,000


      Series C


      07/26/2022


      Carmot Therapeutics


      CA


      $160,000,000


      Series D


      02/15/2022


      Kallyope


      NY


      $236,000,000


      Series D


     

    Portfolio companies include:

     

    Recent News: